Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4 Ways De-Risking Maximizes Compound Value | Contract Pharma

What are you searching for?

Sign in
Infographics

4 Ways De-Risking Maximizes Compound Value

View BioIVT's infographic to learn about how you can leverage your data to showcase your compound in ways that will maximize its value.

Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early in vitro testing and preemptively demonstrating low risk data.

ADME/DMPK and Drug-Drug Interaction studies only cost a small fraction of the potential financial benefits that can be gained by providing this data. The data not only satisfies regulatory requirements and avoids the considerable expense of clinical failures, additional studies and approval delays, but also helps guide the development of the drug candidate and helps with ensuring patient safety.

View our infographic to learn about how you can leverage your data to showcase your compound in ways that will maximize its value.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters